

Asclepius Meditec's hydrogen/oxygen generator helps improve COVID-19 severity

11 August 2020 | News

Asclepius Meditec's hydrogen/oxygen generator has received the Class III Medical Device certificate from China's National Medical Products Administration



An innovative, environmentally friendly treatment with no side effects has been made available to COVID-19 patients, involving the electrolysis of H₂O to produce a mixture of hydrogen and oxygen for human inhalation.

The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD).

In a multicentered, open-label clinical trial described in the article entitled "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial", inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients.

This is a retrospective study, which validated the efficacy and safety of inhaling a H₂-O₂ mixture in patients with COVID-19. The research and clinical trial associated with the study were led by Zhong Nanshan, China's leading pandemic control expert and head of the National Health Commission's expert group fighting COVID-19.

The clinical trial was conducted on 44 patients with COVID-19 whose dyspnea could not be ameliorated after regular treatment in 11 hospitals. After three days of continuous use of the hydrogen/oxygen Generator, AMS-H-03, a device manufactured by Shanghai-based Asclepius Meditec, all 44 patients showed significant improvement compared with 46 patients who received the standard regimen of oxygen alone.

Asclepius Meditec's hydrogen/oxygen generator has received the Class III Medical Device certificate from China's National Medical Products Administration. FDA and CE certification applications for the device are in process.

AMS-H-03 is a hydrogen/oxygen inhalation medical device that the Shanghai-based firm has been working on over a long

period. The core technology is based on a new approach with proven safety which vastly reduces the likelihood of exacerbated pulmonary inflammatory response in COVID-19 patients.